Chemserves Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 13-12-2024
- Paid Up Capital ₹ 2.10 M
as on 13-12-2024
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 2.00 Cr
as on 13-12-2024
- Revenue 19.41%
(FY 2019)
- Profit -879.19%
(FY 2019)
- Ebitda 39.86%
(FY 2019)
- Net Worth -59.59%
(FY 2019)
- Total Assets 7.89%
(FY 2019)
About Chemserves Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.10 M.
The company currently has active open charges totaling ₹2.00 Cr.
Rajendrakumar Holani, Rohitash Mandhana, and Suresh Mandhana serve as directors at the Company.
- CIN/LLPIN
U24100MH2009PTC191943
- Company No.
191943
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Apr 2009
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Chemserves Pharma Private Limited offer?
Chemserves Pharma Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Degreasing Chemicals.
Who are the key members and board of directors at Chemserves Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendrakumar Holani  | Additional Director | 10-Oct-2016 | Current |
| Rohitash Mandhana | Director | 10-Oct-2016 | Current |
| Suresh Mandhana | Director | 16-Feb-2017 | Current |
Financial of Chemserves Pharma.
Chemserves Pharma Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 19.41% increase. The company also saw a substantial fall in profitability, with a 879.19% decrease in profit. The company's net worth observed a substantial decline by a decrease of 59.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemserves Pharma?
In 2019, Chemserves Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Relichem Pharma Private LimitedActive 12 years 3 months
Rajendrakumar Holani, Rohitash Mandhana and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 31 Jul 2015 | ₹2.00 Cr | Open |
How Many Employees Work at Chemserves Pharma?
Unlock and access historical data on people associated with Chemserves Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemserves Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemserves Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
